SEC Info - Ionis Pharmaceuticals Inc.

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM i 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): i April 7, 2024

i IONIS PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in Charter)

i Delaware

(State or Other Jurisdiction of Incorporation)

i 000-19125		i 33-0336973
(Commission File No.)		(IRS Employer Identification No.)

i 2855 Gazelle Court

i Carlsbad, CA i 92010

(Address of Principal Executive Offices and Zip Code)

Registrant’s telephone number, including area code: ( i 760) i 931-9200

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

i ☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

i ☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

i ☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

i ☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading symbol		Name of each exchange on which registered
i Common Stock, $.001 Par Value		i “IONS”		The Nasdaq Stock Market, LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Section 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter).

Emerging growth company i ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01

Other Events.

On April 7, 2024, Ionis Pharmaceuticals, Inc. issued a press release announcing positive results from the Phase 3 Balance study of olezarsen for the treatment of adults with familial chylomicronemia syndrome (FCS).

A copy of this press release is attached as Exhibit 99.1 to this Current Report and incorporated herein by reference.

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	Press Release dated April 7, 2024.

104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Ionis Pharmaceuticals, Inc.

Dated: April 8, 2024	By:	/s/ *Patrick R. O’Neil*

		Patrick R. O’Neil
		Executive Vice President, Chief Legal Officer and General Counsel

This ‘8-K’ Filing	Date	Other Filings

Filed on:	4/8/24	None on these Dates
For Period end:	4/7/24
		List all Filings

Ionis Pharmaceuticals Inc. – ‘8-K’ for 4/7/24

On: Monday, 4/8/24, at 6:04am ET · For: 4/7/24 · Accession #: 1140361-24-18449 · File #: 0-19125

Previous ‘8-K’: ‘8-K’ on 2/29/24 for 2/28/24 · Next & Latest: ‘8-K’ on / for 5/7/24

Current Report — Form 8-K

Filing Table of Contents

‘8-K’ — Current Report

This is an HTML Document rendered as filed. [ Alternative Formats ]

Dates Referenced Herein and Documents Incorporated by Reference